Placement Success: Frank Taffy, JD joins Congruence Therapeutics

Congratulations to Congruence Therapeutics on the appointment of Frank Taffy, JD as Chief Business Officer! Clarissa Desjardins, CEO, is a proven innovator, entrepreneur, and company builder who has assembled a world class team to at Congruence to advance the field of AI/ML enabled computational drug discovery. GSS is privileged to have supported Congruence Therapeutics in their mission to advance their proprietary scalable platform and develop a pipeline of small molecule correctors to address a wide range of diseases and indications that present high unmet need. The future is bright for Congruence and we look forward to witnessing their continued growth and success.

April 23, 2024 · PR Newswire

Congruence Therapeutics Appoints Frank Taffy as Chief Business Officer

Taffy joins from Schrödinger, bringing nearly 25 years of biotechnology industry experience.

Congruence Therapeutics, a computationally driven biotechnology company, has named Frank Taffy, J.D., Chief Business Officer. He most recently led business development at Schrödinger, where he negotiated collaborations with large pharmaceutical and biotechnology companies. At Congruence, he will lead corporate and business development and strategy as the company advances its pipeline of small molecule correctors toward the clinic.

Read the full release

Source: Congruence Therapeutics, via PR Newswire.